[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507142":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":107,"collaborators":109,"id":117,"slug":118,"hasResults":119,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":119,"sex":125,"minAge":126,"maxAge":39,"enrollmentInfo":127,"targetDuration":39,"studyType":130,"phases":131,"briefSummary":133,"conditions":134,"keywords":39,"overallStatus":44,"whyStopped":39,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},{"fullName":5,"class":6},"University Hospital, Basel, Switzerland","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"treatment arm","EXPERIMENTAL","Subjects in the treatment arm will receive 100 μg LSD (first session) and 100 or 200 μg LSD (second session) per os.",[13],"Drug: Lysergic Acid Diethylamide Tartrate",{"label":15,"type":16,"description":17,"interventionNames":18},"control arm","ACTIVE_COMPARATOR","Subjects in the control arm will receive 25 μg LSD (first session) and 25 μg LSD (second session) per os.",[13],[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Lysergic Acid Diethylamide Tartrate","25 μg p.o.",[15],[26],"LSD",{"type":21,"name":22,"description":28,"armGroupLabels":29,"otherNames":30},"100 or 200 μg p.o.",[9],[26],[32],{"name":33,"affiliation":5,"role":34},"Yasmin Schmid, PD Dr. med.","PRINCIPAL_INVESTIGATOR",[36],{"name":33,"role":37,"phone":38,"phoneExt":39,"email":40},"CONTACT",": +41 61 328 68 47",null,"yasmin.schmid@usb.ch",[42,66,80,94],{"facility":43,"status":44,"city":45,"state":39,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"University Hospital Basel, Division of Clinical Pharmacology and Toxicology","RECRUITING","Basel","4031","Switzerland","CH",{"type":50,"coordinates":51},"Point",[52,53],7.57327,47.55839,{"lat":53,"lon":52},[56,58,62,63],{"name":33,"role":37,"phone":57,"phoneExt":39,"email":40},"+41 61 328 68 47",{"name":59,"role":37,"phone":60,"phoneExt":39,"email":61},"Melani Zupari, MSc","+41 61 328 77 42","melani.zuparic@usb.ch",{"name":33,"role":34,"phone":39,"phoneExt":39,"email":39},{"name":64,"role":65,"phone":39,"phoneExt":39,"email":39},"Matthias Liechti, Prof. Dr. med.","SUB_INVESTIGATOR",{"facility":67,"status":44,"city":68,"state":39,"zip":69,"country":47,"countryCode":48,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"University Hospital Geneva, Palliative medicine department","Collonge-Bellerive","1245",{"type":50,"coordinates":71},[72,73],6.20174,46.25061,{"lat":73,"lon":72},[76],{"name":77,"role":37,"phone":78,"phoneExt":39,"email":79},"Michael Ljuslin, Dr. med.","+41 79 553 87 92","michael.ljuslin@hug.ch",{"facility":81,"status":44,"city":82,"state":39,"zip":83,"country":47,"countryCode":48,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Spital Uster AG, Division of Internal Medicine","Uster","8610",{"type":50,"coordinates":85},[86,87],8.72091,47.34713,{"lat":87,"lon":86},[90],{"name":91,"role":37,"phone":92,"phoneExt":39,"email":93},"Sivan Schipper, MD","+41 44 911 12 91","sivan.schipper@spitaluster.ch",{"facility":95,"status":44,"city":96,"state":39,"zip":39,"country":47,"countryCode":48,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative Care","Zurich",{"type":50,"coordinates":98},[99,100],8.55,47.36667,{"lat":100,"lon":99},[103],{"name":104,"role":37,"phone":105,"phoneExt":39,"email":106},"David Blum, Prof Dr med","+41 44 255 37 42","david.blum@usz.ch",{"type":108,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR",[110,112,115],{"name":111,"class":6},"University Hospital, Zürich",{"name":113,"class":114},"Spital Uster AG, Uster, Switzerland","UNKNOWN",{"name":116,"class":6},"University Hospital, Geneva","100507142","phase-2-lysergic-acid-diethylamide-lsd-in-palliative-care-100507142",false,"NCT05883540","Lysergic Acid Diethylamide (LSD) in Palliative Care","Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)","LPC","Inclusion Criteria:\n\n* Age ≥ 22 years.\n* Advanced or End-stage fatal disease of any cause with a life expectancy ≥ 12 weeks and ≤ 2 years\n* Sufficient understanding of the study procedures and risks associated with the study.\n* Participants must be willing to adhere to the study procedures and sign the consent form.\n* Participants must be willing not to drive a traffic vehicle or to operate machines within 24 h after LSD administration.\n* Participants must complete an actual \"Emergency Medical Directive\"\n* Participants with central nervous system (CNS) involvement of cancer are eligible if the following apply:\n\n  * treated and stable CNS lesion(s) OR untreated but asymptomatic\u002Fstable lesions, defined as clinically and\u002For radiologically stable for ≥ 4 weeks before screening\n  * no seizures within ≥ 4 weeks; if on antiepileptic medication: stable dose ≥ 4 weeks and no relevant drug-drug interactions expected\n  * no requirement for high-dose corticosteroids, defined as ≤10 mg prednisone equivalent per day on a stable or decreasing dose\n  * no leptomeningeal metastases\n  * no concomitant therapeutic anticoagulation\n\nExclusion Criteria:\n\n* Life expectancy \\< 12 weeks\n* Known hypersensitivity to LSD\n* Requiring ongoing concomitant therapy with a psychoactive prescription drug which might interfere with the study drug, and unable or unwilling to comply with the washout period.\n* Current use of a potent drug CYP2D6 inhibitor\n* Women who are pregnant or nursing or intend to become pregnant during the course of the study.\n* Somatic disorders including CNS involvement of cancer, untreated epilepsy with a history of generalized grand-mal seizures, history of delirium, end-stage heart failure (NYHA IV), untreated hypertension or insufficiently treated hypertension, angina pectoris, severe liver disease or severely impaired renal function, or other that in the judgement of the investigators pose too great potential for side effects.\n* Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant.\n* Participation in another study with an investigational drug within the 30 days preceding and during the present study\n* concomitant diagnosis of past or present psychotic disorder, first-degree relative with psychotic disorders\n* concomitant diagnosis of past or present bipolar disorder\n* current delirium\n* substance use disorder (within the last 2 months, except nicotine, opioids used for analgesia, and benzodiazepine treatment for anxiety).\n* Weight \\< 45 kg\n* Suicidal ideation with active intent or plan to act on suicidal thoughts as assessed by the treating investigator.\n* CNS involvement of cancer if\n\n  * CNS disease is unstable or high-risk, including clinically and\u002For radiologically progressive lesions, signs of raised intracranial pressure, radiologically uncontrolled edema, need for escalating corticosteroid doses, or any neurological condition judged to pose too excessive risk.\n  * CNS-directed therapy (surgery and\u002For radiation) within ≤ 4 weeks","ALL","22 Years",{"count":128,"type":129},60,"ESTIMATED","INTERVENTIONAL",[132],"PHASE2","Background: Terminally ill patients often experience significant psychosocial distress having depressed mood, death anxiety, pain, and an overall poor quality of life. Recent evidence from pilot studies suggests that serotonergic hallucinogens including lysergic acid diethylamide (LSD) and psilocybin produce significant and sustained reductions of depressive symptoms and anxiety, along with increases in quality of life, and life meaning in patients suffering from life-threatening diseases. Additionally, serotonergic hallucinogens may produce antinociceptive effects.\n\nObjective and Design: The study aims to evaluate effects of LSD on psychosocial distress in 60 patients suffering from an advanced or end-stage fatal disease with a life expectancy ≥12wks and ≤2yrs in an active placebo-controlled double-blind parallel study. Patients will be allocated in a 2:1 ratio to one of the two intervention arms receiving either two moderate to high doses of LSD (100 µg and 100 µg or 100 µg and 200 µg) as intervention and two low doses of LSD (25 µg and 25 µg) as active-placebo control.",[135,136,137,138,139,140,141,142,143,144],"Palliative Care","Pain","Anxiety","Depression","Demoralization","Psychological Distress","Quality of Life","Caregiver Burden","Fear of Death","Existential Distress","2026-04-23",{"date":147,"type":148},"2026-04-29","ACTUAL",{"date":150,"type":148},"2024-06-09",{"date":152,"type":129},"2028-05",{"name":5,"class":6},4]